Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of INS068 vs insulin glargine in type 2 diabetes mellitus
CTR20230085Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2023
- Modality
- Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin sudelidec in type 2 diabetes mellitus (T2DM), sponsored by Hengrui Therapeutics. Started Jan 2023; status: completed.
02
Drugs
insulin sudelidec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20230085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230085.